[Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases].
In an open study with 306 hospitalized patients with obstructive airway diseases (149 males aged 57.2 +/- 13.0 years, 157 females aged 52.2 +/- 13.9 years), the tolerance of the new sustained-release theophylline preparation Uniphyllin was investigated. The duration of treatment was 3.1 +/- 1.3 weeks (males) or 2.9 +/- 1.2 weeks (females), respectively. For 75% of the male and 85% of the female patients a single evening dosage was sufficient. The number of side effects necessitating discontinuance of the theophylline therapy in females was three times that observed in males. Altogether, the 7.8% drop-out rate was very low, considering the seriously ill patients participating in the study. Accordingly, the new sustained-release theophylline preparation has been tolerated particularly well.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013806:Theophylline / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D013806:Theophylline
Zur Verträglichkeit eines neuen oralen Langzeit-Theophyllins bei Patienten mit obstruktiven Atemwegserkrankungen.